HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 08-03-2007, 09:49 AM   #1
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,780
for those on lapatinib, statistics on %s w different side effects

treatment suggestions rather lame (those on this board have done better, I think). Again, the full article is free

OPEN ACCESS: Lapatinib-Associated Toxicity and Practical Management Recommendations [The Oncologist]
Lapatinib is an oral receptor tyrosine kinase inhibitor, inhibiting both the ErbB-1 and ErbB-2 receptors. Lapatinib has been shown to have activity in ErbB-2-overexpressing breast cancer in several phase II and III clinical trials. Specifically, lapatinib is effective in patients with metastatic breast cancer, with inflammatory breast cancer, and possibly, with brain metastases. An ongoing clinical trial and another anticipated clinical trial will investigate lapatinib as adjuvant treatment in early-stage disease. Lapatinib has specific toxicities, the most common being diarrhea and rash. Cardiac toxicity is rarely seen with lapatinib. This paper reviews lapatinib-associated toxicities and provides practical management recommendations based on available data.
Lani is offline   Reply With Quote
Old 08-03-2007, 10:57 AM   #2
Lala
Senior Member
 
Lala's Avatar
 
Join Date: Feb 2006
Location: South Florida
Posts: 131
Lani
Where did you get this information? What paper ?
I have been on Tykerb / Lapatinib for months now.
I did have the common side effects but I do not see the % that you are referring to. It seems you only posted part of the article...
__________________
Lala
DX Fall05 Stage 4 er+ pr+ her2+ liver and bone mets
DX Fall06 Brain mets, Brain mets gone Spring 2007
Lala is offline   Reply With Quote
Old 08-03-2007, 11:02 AM   #3
Lani
Senior Member
 
Join Date: Mar 2006
Posts: 4,780
the full article is posted free online (hence "open acess")

It is from a journal called Oncologist (it was in square brackets) .just google The Oncologist and find the article in the latest edition, hot off the press.

It will include all the stats. Sorry I am not good at "linking"
Lani is offline   Reply With Quote
Old 08-03-2007, 09:09 PM   #4
Lolly
Senior Member
 
Lolly's Avatar
 
Join Date: Aug 2001
Location: Oregon
Posts: 1,756
Here's the link:

http://theoncologist.alphamedpress.o.../full/12/7/756
__________________
Sept.'99 - Dx.Stage IIIB, IDC ER/PR-, HER2+++ by IHC, confirmed '04 by FISH. Left MRM, AC x's 4, Taxol x's 4, 33 Rads, finishing Tx May 2000. Jan.'01 - local/regional recurrence, Stage IV. Herceptin/Navelbine weekly till NED August 2001, then maintenance Herceptin. Right Mast. April 2002. Local/Regional recurrence April '04, Herceptin plus/minus chemo until May '07. Gemzar added from Feb.'07-April '07; Tykerb/Abraxane until August '07, back on Herceptin plus Taxotere and Xeloda Sept. '07. Stopped T/X Nov. '07, stopped Herceptin Dec. '07, started Avastin/Taxol/Carboplatin Dec. '07. Progression in chest skin, stopped TAC March '03, started radiation.

Herceptin has served as the "Backbone" of my treatment strategy for over 6 years, giving me great quality of life. In 2005, I was privileged to participate in the University of Washington/Seattle HER2 Vaccine Trial.
Lolly is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:46 PM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter